Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 593 participants.
Also called NCT01658501
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 593 participants
- Sponsor
- PhaseBio Pharmaceuticals Inc.
- Registry
-
NCT01658501
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01658501. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- 50 mg PB1023
- Intervention (Drug)
- 70 mg PB1023
- Intervention (Drug)
- 100 mg PB1023
- Intervention (Drug)
- Placebo (0.9% Sodium Chloride)
- Intervention (Drug)
- Victoza®
- Intervention (Other)
- Diet and Exercise
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sulfonylurea
- Intervention (Drug)
- Metformin and Sulfonylurea
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
Record details
- Record id
cardio:ct-nct01658501- Content hash
7fb11ce08415198ad81149726cb858c935b22fb3b9baf41a9a78df88487393d9